Antioxidants and the bioactivity of endothelium-derived nitric oxide

Cardiovascular Research

Volumn 47, Issue 3, 2000, Pages 426-435

  Tomasian, Douglas ^a   Keaney Jr , John F ^a   Vita, Joseph A ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Endothelial factors; Endothelial function; Free radicals; Nitric oxide

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CATALASE; FLAVONOID; FREE RADICAL; GLUTATHIONE PEROXIDASE; NITRIC OXIDE; PROBUCOL; SUPEROXIDE; SUPEROXIDE DISMUTASE; TETRAHYDROBIOPTERIN;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIETARY INTAKE; DRUG EFFECT; DRUG MECHANISM; HUMAN; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VITAMIN SUPPLEMENTATION;

ANIMALS; ANTIOXIDANTS; ARTERIOSCLEROSIS; ASCORBIC ACID; DIETARY SUPPLEMENTS; ENDOTHELIUM, VASCULAR; FLAVONOIDS; HUMANS; LIPID PEROXIDATION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; VITAMIN E;

EID: 0034682912     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(00)00103-6     Document Type: Review

References (141)

1. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:1980;373-376.
2. Ignarro L.J., Buga G.M., Wood K.S., Byrns R.E., Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. USA. 84:1987;9265-9269.
3. Stamler J.S., Singel D.J., Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science. 258:1992;1898-1902.
4. Moncada S., Higgs A. The L-arginine nitric oxide pathway. N. Engl. J. Med. 329:1993;2002-2012.
5. Gokce N., Keaney J.F., Jr Vita J.A. Endotheliopathies: clinical manifestations of endothelial dysfunction. Loscalzo J., Shafer A.I. Thrombosis and hemorrhage. 1998;901-924 Williams and Wilkins, London.
6. Keaney J.F. Jr., Vita J.A. Atherosclerosis, oxidative stress and antioxidant protection in endothelium-derived relaxing factor action. Prog. Cardiovasc. Dis. 38:1995;129-154.
7. Sies H. What is oxidative stress. Keaney J.F. Jr. Oxidative stress and vascular disease. 2000;1-8 Kluwer, Boston.
8. Michel T., Feron O. Nitric oxide synthases: which, where, how, and why? J. Clin. Invest. 100:1997;2146-2152.
9. Furchgott R. Role of endothelium in responses of vascular smooth muscle. Circ. Res. 53:1983;557-573.
10. Young M.A., Vatner S.F. Blood flow and endothelium-mediated vasomotion of iliac arteries in conscious dogs. Circ Res. 61:1987;II88.
11. Arnold W.P., Mittal C.K., Katsuki S., Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3′,5′-cyclic monophosphate levels in various tissue preparations. Proc. Natl. Acad. Sci. USA. 74:1977;3203-3207.
12. Lincoln T.M., Cornwell T.L. Intracellular cyclic GMP receptor proteins. FASEB J. 7:1993;328-338.
13. Bolotina V.M., Najibi S., Palacino J.J., Pagano P.J., Cohen R.A. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature. 368:1994;850-853.
14. Radomski M.W., Palmer R.M., Moncada S. Characterization of the L-arginine:nitric oxide pathway in human platelets. Br. J. Pharmacol. 101:1990;325-328.
15. Kubes P., Suzuki M., Granger D.N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. USA. 88:1991;4651-4655.
16. Garg U.C., Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest. 83:1989;1774-1777.
17. Ludmer P.L., Selwyn A.P., Shook T.L., et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med. 315:1986;1046-1051.
18. Cox D.A., Vita J.A., Treasure C.B., et al. Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation. 80:1989;458-465.
19. Creager M.A., Cooke J.P., Mendelsohn M.E., et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J. Clin. Invest. 86:1990;228-234.
20. Celermajer D.S., Sorensen K.E., Gooch V.M., et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 340:1992;1111-1115.
21. Lefroy D.C., Crake T., Uren N.G., Davies G.J., Maseri A. Effect of inhibition of nitric oxide synthesis on epicardial coronary artery caliber and coronary blood flow in humans. Circulation. 88:1993;43-54.
22. Quyyumi A.A., Dakak N., Andrews N.P., et al. Nitric oxide activity in the human coronary circulation. Impact of risk factors for atherosclerosis. J. Clin. Invest. 95:1995;1747-1755.
23. Lieberman E.H., Gerhard M.D., Uehata A., et al. Flow-induced vasodilation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease. Am. J. Cardiol. 78:1996;1210-1214.
24. Vita J.A., Treasure C.B., Yeung A.C., et al. Patients with evidence of coronary endothelial dysfunction as assessed by acetylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of catecholamines. Circulation. 85:1992;1390-1397.
25. Golino P., Piscione F., Willerson J.T., et al. Divergent effects of serotonin on coronary artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N. Engl. J. Med. 324:1991;641-648.
26. Haynes W.G., Noon J.P., Walker B.R., Webb D.J. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J. Hypertens. 11:1993;1375-1380.
27. Meredith I.T., Currie K.E., Anderson T.J., Roddy M.A., Ganz P., Creager M.A. Postischemic vasodilation in human forearm is dependent on endothelium-derived nitric oxide. Am. J. Physiol. 270:1996;H1435-H1440.
28. Gilligan D.M., Panza J.A., Kilcoyne C.M., Waclawiw M.A., Casino P.R., Quyyumi A.A. Contribution of endothelium-derived nitric oxide to exercise-induced vasodilation. Circulation. 90:1994;2853-2858.
29. Simon D.I., Stamler J.S., Loh E., Loscalzo J., Francis S.A., Creager M.A. Effect of nitric oxide synthase inhibition on bleeding time in humans. J. Cardiovasc. Pharmacol. 26:1995;339-342.
30. Adams M.R., Jessup W., Hailstones D., Celermajer D.S. L-Arginine reduces human monocyte adhesion to vascular endothelium and endothelial expression of cell adhesion molecules. Circulation. 95:1997;662-668.
31. de Graaf J.C., Banga J.D., Moncada S., Palmer R.M., de Groot P.G., Sixma J.J. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation. 85:1992;2284-2290.
32. Bossaller C., Habib G.B., Yamamoto H., Williams C., Wells S., Henry P.D. Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5′-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta. J. Clin. Invest. 79:1987;170-174.
33. Sorensen K.E., Celermajer D.S., Georgakopoulos D., Hatcher G., Betteridge D.J., Deanfield J.E. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein (a) level. J. Clin. Invest. 93:1994;50-55.
34. Vita J.A., Treasure C.B., Nabel E.G., et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 81:1990;491-497.
35. Nishimura R.A., Lerman A., Chesebro J.H., et al. Epicardial vasomotor responses to acetylcholine are not predicted by coronary atherosclerosis as assessed by intracoronary ultrasound. J. Am. Coll. Cardiol. 26:1995;41-49.
36. Treasure C.B., Klein J.L., Vita J.A., et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation. 87:1993;86-93.
37. Nitenberg A., Valersi P., Sachs R., Dali M., Aptecar E., Attali J.R. Impairment of coronary vascular reserve in and ACH-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes. 42:1993;1017-1025.
38. Nitenberg A., Antony I., Foult J.M. Acetylcholine-induced coronary vasoconstriction in young, heavy smokers with normal coronary arteriographic findings. Am. J. Med. 95:1993;71-77.
39. Celermajer D.S., Sorensen K., Ryalls M., et al. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J. Am. Coll. Cardiol. 22:1993;854-858.
40. Clarkson P., Celermajer D.S., Powe A.J., Donald A.E., Henry R.M., Deanfield J.E. Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation. 96:1997;3378-3383.
41. Cooke J.P., Singer A.H., Tsao P., Zera P., Rowan R.A., Dillingham M.E. Antiatherogenic effects of L-arginine in hypercholesterolemic rabbits. J. Clin. Invest. 90:1992;1168-1172.
42. Libby P. Molecular basis of the acute coronary syndromes. Circulation. 91:1995;2844-2850.
43. Gordon J.B., Ganz P., Nabel E.G., et al. Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise. J. Clin. Invest. 83:1989;1946-1952.
44. Yeung A.C., Vekshtein V.I., Krantz D.S., et al. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N. Engl. J. Med. 325:1991;1551-1556.
45. Vita J.A., Treasure C.B., Ganz P., Cox D.A., Fish R.D., Selwyn A.P. Control of shear stress in the epicardial coronary arteries of humans: impairment by atherosclerosis. J. Am. Coll. Cardiol. 14:1989;1193-1199.
46. Levine G.N., Keaney J.F. Jr., Vita J.A. Cholesterol reduction in cardiovascular disease: Clinical benefits and possible mechanisms. N. Engl. J. Med. 332:1995;512-521.
47. Suwaidi J.A., Hamasaki S., Higano S.T., Nishimura R.A., Holmes D.R., Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 101:2000;948-954.
48. Witztum J.L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88:1991;1785-1792.
49. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340:1999;115-126.
50. Gryglewski R.J., Palmer R.M., Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. 320:1986;454-456.
51. Beckman J.S., Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am. J. Physiol. 271:1996;C1424-C1437.
52. Ignarro L.J., Byrns R.E., Buga G.M., Wood K.S., Chaudhuri G. Pharmacological evidence that endothelium-derived relaxing factor is nitric oxide: use of pyrogallol and superoxide dismutase to study endothelium dependent and nitric oxide elicited vascular smooth muscle relaxation. J. Pharmacol. Exp. Ther. 244:1988;181-189.
53. Mugge A., Elwell J.K., Peterson T.E., Harrison D.G. Release of intact endothelium-derived relaxing factor depends on endothelial superoxide dismutase activity. Am. J. Physiol. 260:1991;C219-C225.
54. Ohara Y., Peterson T.E., Harrison D.G. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest. 91:1993;2546-2551.
55. Rajagopalan S., Kurz S., Munzel T., et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J. Clin. Invest. 97:1996;1916-1923.
56. Tesfamariam B., Cohen R.A. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am. J. Physiol. 263:1992;H321-H326.
57. Pagano P.J., Ito Y., Tornheim K., Gallop P., Cohen R.A. The superoxide generating system in rabbit aorta resembles NAD(P)H oxidase. Circulation. 88:1993;I467.
58. Pritchard K.A. Jr., Groszek L., Smalley D.M., et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ. Res. 77:1995;510-518.
59. Mugge A., Elwell J.H., Peterson T.E., Hofmeyer T.G., Heistad D.D., Harrison D.G. Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxations in cholesterol-fed rabbits. Circ. Res. 69:1991;1293-1300.
60. Nègre-Salvayre A., Pieraggi M.T., Mabile L., Salvayre R. Protective effect of 17-beta-estradiol against the cytotoxicity of minimally oxidized LDL to cultured bovine aortic endothelial cells. Atherosclerosis. 99:1992;207-217.
61. Quinn M.T., Parthasarathy S., Fong L.G., Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc. Natl. Acad. Sci. USA. 84:1987;2995-2998.
62. Chin J.H., Azhar S., Hoffman B.B. Inactivation of endothelium-derived relaxing factor by oxidized lipoproteins. J. Clin. Invest. 89:1992;10-18.
63. O'Donnell V.B., Taylor K.B., Parthasarathy S., et al. 15-Lipoxygenase catalytically consumes nitric oxide and impairs activation of guanylate cyclase. J. Biol. Chem. 274:1999;20083-20091.
64. Liao J.K., Shin W.S., Lee W.Y., Clark S.L. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J. Biol. Chem. 270:1995;319-324.
65. Kugiyama K., Kerns S.A., Morrisett J.D., Roberts R., Henry P.D. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature. 344:1990;160-162.
66. Keaney J.F. Jr., Guo Y., Cunningham D., Shwaery G.L., Vita J.A. Vascular incorporation of alpha-tocopherol prevents endothelial dysfunction due to oxidized LDL by inhibiting protein kinase C stimulation. J. Clin. Invest. 98:1996;386-394.
67. Schmidt K., Klatt P., Graier W.F., Kostner G.M., Kukovetx W.R. High-density lipoprotein antagonizes the inhibitory effects of oxidized low-density lipoprotein and lysolecithin on soluble guanylyl cyclase. Biochem. Biophys. Res. Commun. 182:1992;302-308.
68. Heitzer T., Yla-Herttuala S., Luoma J., et al. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. Circulation. 93:1996;1346-1353.
69. Tamai O., Matsuoka H., Itabe H., Wada Y., Kohno K., Iamaizumi T. Single LDL apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans. Circulation. 95:1997;76-82.
70. Anderson T.J., Meredith I.T., Charbonneau F., et al. Endothelium-dependent coronary vasomotion relates to susceptibility of LDL to oxidation in humans. Circulation. 93:1996;1647-1650.
71. Biegelsen E.S., Vita J.A. Human studies of antioxidants and vascular function. Keaney J.F. Jr. Oxidative stress and vascular disease. 1999;213-243 Kluwer, Boston.
72. Duffy S.J., Vita J.A., Keaney J.F. Jr. Antioxidants and endothelial function. Heart Failure. 15:1999;135-152.
73. Keaney J.F. Jr., Gaziano J.M., Xu A., et al. Dietary antioxidants preserve endothelium-dependent vessel relaxation in cholesterol-fed rabbits. Proc. Natl. Acad. Sci. USA. 90:1993;11880-11884.
74. Andersson T.L.G., Matz J., Ferns G.A.A., Anggard E.E. Vitamin E reverses cholesterol-induced endothelial dysfunction in the rabbit coronary circulation. Atherosclerosis. 111:1994;39-45.
75. Keaney J.F. Jr., Gaziano J.M., Xu A., et al. Low-dose alpha-tocopherol improves and high-dose alpha-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits. J. Clin. Invest. 93:1994;844-851.
76. Diaz M.N., Frei B., Vita J.A., Keaney J.F. Jr. Antioxidants and atherosclerotic heart disease. N. Engl. J. Med. 337:1997;408-417.
77. Cathcart M.K., Morel D.W., Chisolm G.M. Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic. J. Leukoc. Biol. 38:1985;341-346.
78. Navab M., Imes S.S., Hama S.Y., et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest. 88:1991;2039-2046.
79. Keegan A., Walbank H., Cotter M.A., Cameron N.E. Chronic vitamin E treatment prevents defective endothelium-dependent relaxation in diabetic rat aorta. Diabetologia. 38:1995;1475-1478.
80. Gilligan D.M., Sack M.N., Guetta V., et al. Effect of antioxidant vitamins on low density lipoprotein oxidation and impaired endothelium-dependent vasodilation in patients with hypercholesterolemia. J. Am. Coll. Cardiol. 24:1994;1611-1617.
81. McDowell I.F., Brennan G.M., McEneny J., et al. The effect of probucol and vitamin E treatment on the oxidation of low-density lipoprotein and forearm vascular responses in humans. Eur. J. Clin. Invest. 24:1994;759-765.
82. Gazis A., White D.J., Page S.R., Cockcroft J.R. Effect of oral vitamin E (alpha-tocopherol) supplementation on vascular endothelial function in Type 2 diabetes mellitus. Diabet. Med. 16:1999;304-311.
83. Chowienczyk P.J., Kneale B.J., Brett S.E., Paganga G., Jenkins B.S., Ritter J.M. Lack of effect of vitamin E on L-arginine responsive endothelial dysfunction in patients with mild hypercholesterolemia and coronary artery disease. Clin. Sci. 94:1998;129-134.
84. Elliott T.G., Barth J.D., Mancini G.B.J. Effects of vitamin E on endothelial function in men after myocardial infarction. Am. J. Cardiol. 76:1995;1188-1190.
85. Neunteufl T., Kostner K., Katzenschlager R., Zehetgruber M., Maurer G. Additional benefit of vitamin E supplementation to simvastatin therapy on vasoreactivity of the brachial artery of hypercholesterolemic men. J. Am. Coll. Cardiol. 32:1998;711-716.
86. Kugiyama K., Motoyama T., Doi H., et al. Improvement of endothelial vasomotor dysfunction by treatment with alpha-tocopherol in patients with high remnant lipoproteins levels. J. Am. Coll. Cardiol. 33:1999;1512-1518.
87. Heitzer T., Yla H.S., Wild E., Luoma J., Drexler H. Effect of vitamin E on endothelial vasodilator function in patients with hypercholesterolemia, chronic smoking or both. J. Am. Coll. Cardiol. 33:1999;499-505.
88. Stewart-Lee A.L., Forster L.A., Nourooz-Zadeh J., Ferns G.A.A., Anggard E.E. Vitamin E protects against impairment of endothelium-mediated relaxations in cholesterol-fed rabbits. Arterioscler. Thromb. 14:1994;494-499.
89. Anderson T.J., Meredith I.T., Yeung A.C., Frei B., Selwyn A., Ganz P. The effect of cholesterol lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N. Engl. J. Med. 332:1995;488-493.
90. Ting H.H., Timimi F.K., Boles K.S., Creager S.J., Ganz P., Creager M.A. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Clin. Invest. 97:1996;22-28.
91. Levine G.N., Frei B., Koulouris S.N., Gerhard M.D., Keaney J.F. Jr., Vita J.A. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 96:1996;1107-1113.
92. Gokce N., Keaney J.F. Jr., Frei B., et al. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 99:1999;3234-3240.
93. Hornig B., Arakawa N., Kohler C., Drexler H. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation. 97:1998;363-368.
94. Motoyama T., Kawano H., Kugiyama K., et al. Endothelium-dependent vasodilation in the brachial artery is impaired in smokers: effect of vitamin C. Am. J. Physiol. 273:1997;H1644-H1650.
95. Chambers J.C., McGregor A., Jean-Marie J., Obeid O.A., Kooner J.S. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation. 99:1999;1156-1160.
96. Kugiyama K., Motoyama T., Hirashima O., et al. Vitamin C attenuates abnormal vasomotor reactivity in spasm coronary arteries in patients with coronary spastic angina. J. Am. Coll. Cardiol. 32:1998;103-109.
97. Ting H.H., Timimi F.K., Haley E.A., Roddy M.A., Ganz P., Creager M.A. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. Circulation. 95:1997;2617-2622.
98. Taddei S., Virdis A., Ghiadoni L., Magagna A., Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation. 97:1998;2222-2229.
99. Sherman DL, Keaney JF Jr, Biegelsen ES, Duffy SJ, Coffman JD, Vita JA. Pharmacological concentrations of ascorbic acid are required for the beneficial effects on endothelial vasomotor function in hypertension. Hypertension (in press).
100. Solzbach U., Hornig B., Jeserich M., Just H. Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation. 96:1997;1513-1519.
101. Heitzer T., Just H., Munzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation. 94:1996;6-9.
102. Frei B., England L., Ames B.N. Ascorbate is an outstanding antioxidant in human blood plasma. Proc. Natl. Acad. Sci. USA. 86:1989;6377-6381.
103. Jackson T.S., Xu A., Vita J.A., Keaney J.F. Jr. Ascorbate prevents the interaction of superoxide and nitric oxide only at very high physiological concentrations. Circ. Res. 83:1998;916-922.
104. Meister A. Glutathione-ascorbic acid antioxidant system in animals. J. Biol. Chem. 269:1994;9397-9400.
105. Kissner R., Nauser T., Bugnon P., Lye P.G., Koppenol W.H. Formation and properties of peroxynitrite as studied by laser flash photolysis, high pressure stopped-flow technique, and pulsed radiolysis. Chem. Res. Toxicol. 10:1997;1285-1292.
106. Malinski T., Taha Z., Grunfeld S., Patton S., Kapturczak M., Tomboulian P. Diffusion of nitric oxide in the aorta wall monitored in situ by porphyrinic microsensors. Biochem. Biophys. Res. Commun. 193:1993;1076-1082.
107. Ito K., Akita H., Kanazawa K., Yamada S., Terashima M. Comparison of effects of ascorbic acid on endothelium-dependent vasodilation in patients with chronic congestive heart failure secondary to idiopathic dilated cardiomyopathy versus patients with effort angina pectoris secondary to coronary artery disease. Am. J. Cardiol. 82:1998;762-767.
108. Ghigo D., Alessio P., Foco A., et al. Nitric oxide synthesis is impaired in glutathione-depleted human umbilical vein endothelial cells. Am. J. Physiol. 265:1993;C728-C732.
109. Hobbs A.J., Fukoto J.M., Ignarro L.J. Formation of free nitric oxide from L-arginine by nitric oxide synthase: Direct enhancement of generation by superoxide dismutase. Proc. Natl. Acad. Sci. USA. 91:1994;10992-10996.
110. Gorren A.C., Schrammel A., Schmidt K., Mayer B. Thiols and neuronal nitric oxide synthase: complex formation, competitive inhibition, and enzyme stabilization. Biochemistry. 36:1997;4360-4366.
111. Vita J.A., Frei B., Holbrook M., Gokce N., Leaf C., Keaney J.F. Jr. L-2-oxothiazolidine-4-carboxylic acid reverses endothelial dysfunction in patients with coronary artery disease. J. Clin. Invest. 101:1998;1408-1414.
112. Kugiyama K., Ohgushi M., Motoyama T., et al. Intracoronary infusion of reduced glutathione improves endothelial vasomotor response to acetylcholine in human coronary circulation. Circulation. 97:1998;2299-2301.
113. Prasad A., Andrews N.P., Padder F.A., Husain M., Quyyumi A.A. Glutathione reverses endothelial dysfunction and improves nitric oxide bioavailability. J. Am. Coll. Cardiol. 34:1999;507-514.
114. Hofmann H., Schmidt H.H.H.W. Thiol dependence of nitric oxide synthase. Biochemistry. 34:1995;13443-13452.
115. Heller R., Munscher-Paulig F., Grabner R., Till U. L-Ascorbic acid potentiates nitric oxide synthesis in endothelial cells. J. Biol. Chem. 274:1999;8254-8260.
116. Huang A., Venema R.C., Vita J.A., Keaney J.F. Jr. Ascorbic acid enhances endothelial nitric oxide production in a tetrahydrobiopterin-dependent manner. Circulation. 100:1999;I702.
117. Stroes E., Kastelein J., Cosentino F., et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J. Clin. Invest. 99:1997;41-46.
118. Keaney J.F. Jr., Xu A., Cunningham D.C., Jackson T., Frei B., Vita J.A. Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide production. J. Clin. Invest. 95:1995;2520-2529.
119. Wiseman S.A., Balentine D.A., Frei B. Antioxidants in tea. Crit. Rev. Food Sci. Nutr. 37:1997;705-718.
120. Lairon D., Amiot M.J. Falvonoids in food and natural antioxidants in wine. Curr. Opin. Lipid. 10:1999;23-28.
121. Muldoon M.F., Kritchevsky S.B. Flavonoids and heart disease. Br Med J. 312:1996;458-459.
122. Flesch M., Schwarz A., Bohm M. Effects of red and white wine on endothelium-dependent vasorelaxation of rat aorta and human coronary arteries. Am. J. Physiol. 275:1998;H1183-H1190.
123. Stein J.H., Keevil J.G., Wiebe D.A., Aeschlimann S., Folts J.D. Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. Circulation. 100:1999;1050-1055.
124. Garcia C.E., Kilcoyne C.M., Cardillo C., Cannon R.O. III, Quyyumi A.A., Panza J.A. Effect of copper-zinc superoxide dismutase on endothelium-dependent vasodilation in patients with essential hypertension. Hypertension. 26:1995;863-868.
125. Garcia C.E., Kilcoyne C.M., Cardillo C., Cannon R.O., Quyyumi A.A., Panza J.A. Evidence that endothelial dysfunction in patients with hypercholesterolemia is not due to increased extracellular nitric oxide breakdown by superoxide anions. Am. J. Cardiol. 76:1995;1157-1161.
126. Carew T.E., Schwenke D.C., Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc. Natl. Acad. Sci. USA. 84:1987;7725-7729.
127. Keaney J.F. Jr. Antioxidants and atherosclerosis: animal studies. Keaney J.F. Jr. Oxidative stress and vascular disease. 2000;195-211 Kluwer, Boston.
128. Gaziano J.M. Antioxidants and cardiovascular disease. Keaney J.F. Jr. Oxidative stress and vascular disease. 1999;245-258 Kluwer, Boston.
129. Rimm E.B., Stampfer M.J., Ascherio A., Giovannucci E., Colditz G.A., Willett W.C. Vitamin E consumption and the risk of coronary heart disease in men. N. Engl. J. Med. 328:1993;1450-1456.
130. Stampfer M.J., Hennekens C.H., Manson J.E., Colditz G.A., Rosner B., Willett W.C. Vitamin E consumption and the risk of coronary disease in women. N. Engl. J. Med. 328:1993;1444-1449.
131. Enstrom J.E., Kanim L.E., Klein M.A. Vitamin C intake and mortality among a sample of the United States population. Epidemiology. 3:1992;194-202.
132. Nyyssonen K., Parviainen M.T., Salonen R., Tuomilehto J., Salonen J.T. Vitamin C deficiency and risk of myocardial infarction: prospective population study of men from eastern Finland. Br Med J. 314:1997;634-638.
133. Stephens N.G., Parsons A., Schofield P.M., Kelly F., Cheeseman K., Mitchinson M.J. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 347:1996;781-786.
134. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 354:1999;447-455.
135. Yusuf S., Dagenais G., Pogue J., Bosch J., Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342:2000;154-160.
136. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 330:1994;1029-1035.
137. Hennekens C.H., Buring J.E., Manson J.E., et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 334:1996;1145-1149.
138. Omenn G.S., Goodman G.E., Thornquist M.D. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 334:1996;1150-1155.
139. Hodis H.N., Mack W.J., LaBree L., et al. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. J Am Med Assoc. 273:1995;1849-1854.
140. Kritchevsky S.B., Shimakawa T., Tell G.S., et al. Dietary antioxidants and carotid artery wall thickness: The ARIC study. Circulation. 92:1995;2142-2150.
141. Walldius G., Erikson U., Olsson A.G., et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am. J. Cardiol. 74:1994;875-883.